ABOUT US

About Us

Eurasia Huizhi (Beijing) Medical Research Co., Ltd

Eurasia Huizhi (Beijing) Medical Research Co., Ltd. is a Contract Research Organization (CRO) that provides specialized clinical trial services to pharmaceutical companies. The company adheres to the principles of integrity, win-win cooperation, diligence, and professionalism, offering high-quality solutions to its partners for new drug development. Through superior approaches, we help clients enhance R&D efficiency, reduce R&D risks, save R&D costs, and accelerate the commercialization of their products. With patients at the core, guided by clinical value, and aiming to meet unmet clinical needs, we continuously create new value for the healthcare industry.

We have over 17 years of experience in clinical trial research, consistently pursuing professional industry quality standards. With valuable expertise gained from more than 500 projects, we have played a pivotal role in every trial across over 20 research areas, including oncology/hematologic malignancies, endocrinology, neuropsychiatry, cardiovascular, digestive, respiratory, rheumatologic and immunologic disorders, and otolaryngology.

17 + years

Clinical Trial Research Process

15 + years

Operations Management Expert Team

200 +name

Experienced clinical operations team

500 +

Project Undertaking

200 +

Clinical Trial Research Experience

60 + one

Deep strategic cooperation center, with highly compatible and efficient Phase I clinical resources.

100 +name

Early Clinical Research Expert Team

10 + item

Invention patent

6 + item

Software Copyright

6 Item

National Key Special Project

Corporate culture

Company Vision

Dedicated to becoming a leader in MA solutions for the pharmaceutical industry.

Company Mission

Based in the pharmaceutical industry, we continuously create new value for the health sector.

Entrepreneurial Spirit

Integrity: Upholding trust and honoring commitments for sustainable business operations.

Win-Win: Empathize and Collaborate for Mutual Success

Diligence: Heaven rewards those who work hard with dedication and meticulousness.

Specialization: Pursuing excellence and unlocking innovation

Development History

2019–Present >>> The Moment of Breakthrough

The cumulative number of projects undertaken has exceeded 500. Over 60% of the projects are innovative drug programs. There are more than 10 cell therapy projects. Acquired Suhao Bio (biomaterials for tissue regeneration).

2015-2018 >>> The Period of Running

Established separate subsidiaries for pharmaceutical CRO, medical device CRO, and SMO services. Secured capital investment of 25 million yuan. Obtained 9 pharmaceutical invention patents and 6 software copyrights. Rare disease therapeutic drugs approved for conditional marketing. Undertook a key national R&D project under the 13th Five-Year Plan.

2011-2014>>> The Turning Point

Expand the medical device CRO business Establishment of a Regenerative Medicine R&D Center Innovative service capabilities are at the forefront of the industry.

2006-2010>>> Early Stages

A CRO company was founded, offering import registration and clinical services. Established partnerships with Fortune 100 multinational pharmaceutical companies, including Pierre Fabre. Completed 8 import registration and clinical projects.

MA solution

Image name

Leveraging our professional and technical expertise, we integrate a comprehensive service chain into clinical studies with optimal solutions, helping our partners save time and reduce costs while providing end-to-end support throughout the entire product development process.